Section 122 is unusually bounded. 19 U.S.C. 2132 authorizes a temporary import surcharge of no more than 15 percent ad valorem for no more than 150 days unless Congress extends it. Proclamation 11012 imposed the current 10 percent surcharge effective February 24, 2026, putting the 150-day statutory endpoint on July 24, absent congressional extension or re-invocation. That is the mechanical basis for the deadline now shaping the Greer-Goyal talks. Indian officials reported substantial progress after U.S. Trade Representative Jamieson Greer met Goyal in New Delhi on June 24, 2026. The President later announced an intention to raise the rate to 15 percent, but the live rate on Indian goods has been reported uniformly as 10 percent, and Traverse has seen no implementation notice effecting a 15 percent rate.
The question is not who faces the deadline. It is who controls the next tariff baseline.
Why Section 122 is India's least bad exposure
Goyal's framing rests on the intuition that when the surcharge lapses, U.S. leverage lapses with it. That is the wrong unit of analysis. The expiring item is not the tariff strategy. It is the easiest tariff to price. A fixed, known, capped, sunsetting charge is a comparatively benign exposure. An importer can model a 10 percent charge with a July 24 endpoint. What replaces it is procedural optionality held mainly by Washington, and that optionality is worth more to the party that holds it the more uncertain its exercise.
Two structural features make the current 10 percent narrower than it looks. First, the surcharge does not automatically stack onto Section 232 duties. Proclamation 11012 excludes products already subject to Section 232 tariffs to the extent the Section 232 duty applies, so stacking cannot be assumed without checking the relevant HTS provision and implementation instructions. Second, the surcharge largely tracks the IEEPA-era exemption list, covering critical minerals, energy, many pharmaceutical products and ingredients, certain electronics, passenger vehicles, and goods already under Section 232. American Action Forum analysis estimates that approximately 62 percent of U.S. imports are exempt from Section 122, and that 47 percent remain exempt even after accounting for Section 232. For India that matters because its single largest export category to the United States, pharmaceuticals, sits largely outside the surcharge and is captured, if at all, by a separate Section 232 timetable.
India does not lose every tariff number on July 24. It loses the one live, broad, capped surcharge reference point it can currently model across non-exempt goods. Washington does not get a free hand after July 24 either, but it retains more of the next procedural menu than India does.
What can replace it
Learning Resources removed IEEPA as the administration's fastest tariff platform, but it did not reach Section 232 or Section 301. The practical effect is channeling. Tariff pressure moves from the quickest emergency tool into slower but potentially more durable statutory authorities, making the next fights more record-specific than the IEEPA challenge was.
| Authority | Status on July 24 | Rate | Scope | India relevance |
|---|
| Section 122 | Sunsets absent extension or re-invocation | 10 percent now, 15 percent statutory cap | Broad but heavily exempted | The current fixed reference point that disappears |
| Section 301 forced labor | Proposed, not final | 12.5 percent or 10 percent lower tier, proposed | Broad, subject to final annex and HTS implementation | Candidate post-122 baseline if finalized |
| Section 232 | Live sectoral authorities | Product-specific | Sectoral | Metals, autos, and pharma exposure already outside the 122 clock |
| Second Section 122 | Theoretical and litigation-prone | Up to 15 percent | Broad and uniform | Negotiating pressure, weak as a durable platform |
Section 301 is the most direct candidate for a post-Section 122 baseline, but it is not live yet. USTR's forced-labor proposal of June 2, 2026 would impose a 12.5 percent additional duty on India absent lower-tier treatment, with a 10 percent tier available for economies that meet specified forced-labor or reciprocal-trade criteria, including commitments through an Agreement on Reciprocal Trade. Those are proposed rates rather than final rates. The legal significance is timing. The July 6 comment deadline and July 7 hearing, with post-hearing rebuttal comments due within five days, are the first procedural steps toward a more durable tariff floor after the Section 122 sunset. If finalized, the forced-labor Section 301 action could become the first durable post-122 baseline for India, and unlike the surcharge, it would not carry Section 122's 150-day statutory sunset and would sit within the more familiar Section 301 review and modification framework. A separate structural-excess-capacity investigation flags Indian solar, petrochemicals, steel, textiles, and autos.
Section 232 is different. It is not a broad replacement for Section 122 but the sectoral floor that July 24 does not touch. Steel, aluminum, copper, autos and auto parts, timber, trucks, and certain semiconductors sit under their own proclamations, annexes, HTS instructions, origin rules, and product characterization, with covered steel, aluminum, and copper content subject to a 50 percent rate where the relevant proclamations and HTS instructions apply. Goyal himself has publicly described the 50 percent metals rate as a national-security measure with nothing to do with India specifically. The April 2, 2026 pharmaceutical proclamation matters less because of July 24 than because it shows why July 24 is not India's real exposure date for its largest export category. Generics and biosimilars remain outside the current pharma action, but covered patented products and APIs face a 100 percent default on separate company-specific timetables beginning July 31, 2026 and September 29, 2026, subject to the proclamation, annexes, and implementing instructions, with a Commerce review of generics due within one year. For life-sciences supply chains the relevant dates are July 31, September 29, and the 2027 generics review rather than the Section 122 sunset.
A second Section 122 proclamation is the weakest fallback. The statute does not expressly impose a cooling-off period, but consecutive invocations would invite the obvious anti-circumvention challenge. If the President can restart the 150-day clock indefinitely, the statutory limit loses force. Peter Harrell, writing in Lawfare, concludes that a second proclamation issued immediately after the current one lapses would likely be rejected given Congress's clear intent to limit duration. The Cato Institute analysis, consistent with the nondelegation argument Ilya Somin pressed in the Burlap and Barrel amicus brief, treats the ability to restart as the defect. That makes re-invocation useful as negotiating pressure but weak as a durable tariff platform.
Why this matters for the India deal
The current negotiation recalibrates the February 7, 2026 framework, which set a reciprocal tariff of 18 percent on Indian goods, down from 50 percent, paired with India's removal of the 25 percent Russian-oil penalty and a set of Indian market-access concessions and purchase commitments tied to the State Department Mission 500 goal. The accompanying Fact Sheet records a modification clause stating that if either country changes its agreed tariffs, the other may modify its commitments.
India's objective is not simply a lower U.S. tariff. It is a relative tariff advantage against competing exporters such as Vietnam, Bangladesh, Pakistan, and the broader ASEAN group. The Supreme Court's February 20 ruling and the flat 10 percent Section 122 surcharge weakened the differential India had bargained for, and a clean Section 122 lapse gives every supplier the same zero on that surcharge line. That is why the lapse can weaken India's negotiating position even while temporarily lowering collected duties on non-exempt goods. India has signaled through reporting that it will seek assurances against new tariffs after a deal, wary of further threats if talks stall. That request indicates that India's own negotiators understand the post-deal unilateral tariff risk even as Goyal publicly minimizes the deadline. Officials on both sides have described the talks as close, but no finalization date has been confirmed.
What practitioners should do
For importers of Indian-origin goods, July 24 should be modeled as a reset date rather than a relief date. For each HTS line, counsel should test four scenarios, a clean lapse to MFN, forced-labor Section 301 finalization, existing Section 232 coverage, and agreement-based lower-tier treatment or exclusion. Do not assume Section 301 stacking with Section 232 articles until the final annex and HTS instructions issue, because USTR has proposed exempting articles already subject to Section 232 from that action. Do not assume Section 122 relief for goods whose real exposure already sits in Section 232.
On litigation posture, the Section 122 appeal in the consolidated State of Oregon v. Trump litigation is live, where a 2 to 1 U.S. Court of International Trade ruling on May 7, 2026 found the balance-of-payments predicate unmet. The Federal Circuit has allowed collection to continue through a stay pending appeal, finding the government likely to succeed for stay purposes, but that is not a final merits ruling. Non-plaintiff importers should not assume an automatic refund path. They should evaluate preservation of rights through timely protests on liquidated entries and, where appropriate, follow-on CIT actions, while IEEPA refund claims continue through CBP's developing consolidated entry processing.
Watch the dates
| Date | Event | Why it matters |
|---|
| July 6, 2026 | Section 301 written comments due | Last record-building point before the hearing |
| July 7, 2026 | Section 301 forced-labor hearing | Procedural build-out of a possible replacement tariff |
| July 24, 2026 | Section 122 150-day endpoint | The fixed surcharge reference point disappears |
| July 31, 2026 | Pharma Section 232 first company-specific effective date | Sectoral exposure outside Section 122 |
| September 29, 2026 | Pharma Section 232 second company-specific effective date | Covered patented pharma and API exposure expands under the proclamation timetable |
| CAFC merits ruling, date to be set | Section 122 appeal | Determines durability of 122 as a fallback |
| April 2, 2027 | Commerce generics review deadline | Deferred cliff for India's generic-heavy pharma exports |
Bottom line
July 24 does not eliminate U.S. tariff leverage against India. It eliminates the one live, capped, time-limited tariff number India can currently model, and shifts the fight to slower but potentially more durable authorities under Section 301 and Section 232. Importers of Indian-origin goods should treat the date as a reset rather than relief, and re-check origin, product characterization, HTS classification, the Section 232 floor, and the proposed Section 301 overlay for each line. India-facing counsel should price a pre-deadline tranche not in the headline rate but in whether the text constrains Washington's ability to rebuild tariff pressure after a deal.
What is confirmed and what is analysis
The statutory text of Section 122, the Learning Resources holding, Proclamation 11012's effective date and 10 percent rate, the July 24 math, the February framework terms, and the Section 301 and Section 232 dockets and dates are drawn from primary documents. The expiration asymmetry, the channeling reading of Learning Resources, and the fragility of re-invocation are analysis, and where they rest on contested legal questions they follow named analysts including Harrell in Lawfare and the Cato Institute. The 15 percent rate appears announced but not implemented and is treated as reported. The Section 301 12.5 percent and 10 percent figures are proposed rather than final, and no finalization date for the interim agreement has been confirmed.